PAOG - Under the Radar CBD Biopharma Player Could Offer Major Upside
13 August 2020 - 3:13PM
InvestorsHub NewsWire
Augusut 13, 2020 -- InvestorsHub NewsWire --
via Goldman
Small Cap Research -- PAO Group, Inc. (OTC
- PAOG) is an emerging cannabis and CBD company targeting
growth via two tracks. The Company is in the early stages of
developing a cannabis extract-based therapy to treat various
respiratory diseases and illnesses including COPD and COVID-19.
PAOG also owns a growing cannabis cultivation operation focused on
hemp cultivation.
Investment Higlights (Summary)
Via its recent acquisitions, PAOG has re-positioned itself
as an emerging CBD Biopharma company on a development path to treat
two major respiratory diseases that each represent billions in
potential market sizes. PAOG also acquired a cannabis
cultivation operation generating $300,000 in annual
revenue.
Leveraging a series of favorable studies, the Company is
set to engage a CRO to initiate the process for potential FDA
approval of RespRx, its new flagship COPD
treatment. COPD represents an estimated $14.1B market
by 2025.
After completing a recent 25 patient study
using RespRx to treat COVID-19 symptoms, PAOG is
preparing to commence a similar development pathway for this
disease. Management expects to soon file a CTAP
(Coronavirus Treatment Acceleration Program) application and given
the current pandemic, it is likely to be
fast-tracked.
Next Steps (Summary)
We should note that a number of CBD Biopharma companies are
publicly traded, with market caps ranging as high as $100M or more.
Based on our cursory due diligence we found one firm,
Avianna (OTC
– AVCNF – NR), which is also targeting the COVID-19
arena, that has a current market cap of around $27M. Perhaps as
PAOG moves along the development path on either the COPD or
COVID-19 track, it can trade toward this figure, assuming current
financials and information are available.
Valuation and Conclustion
(Summary)
As progress and milestones on the development path occur, PAOG’s
shares warrant a closer look as they could serve as catalysts to
drive the overall valuation higher for PAOG’s
shares.
See Full Goldman Small Cap Research Report
And Disclosures
SOURCE: Goldman
Small Cap Research
Avicanna (QX) (USOTC:AVCNF)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Avicanna (QX) (USOTC:AVCNF)
Historical Stock Chart
Von Dez 2023 bis Dez 2024
Echtzeit-Nachrichten über Avicanna Inc (QX) (OTCMarkets): 0 Nachrichtenartikel
Weitere Avicanna Inc (QX) News-Artikel